This study is testing a medication called pegozafermin to see if it works and is safe for adults with a liver problem called MASH (also known as NASH) and liver scarring called fibrosis. MASH is a condition where there's fat in the liver, causing damage without alcohol use. Fibrosis means the liver is getting scarred. To join, you must be between 18 and 75 years old, have MASH confirmed by a liver test (biopsy), and have a body mass index (BMI) over 25. People with other liver diseases or severe diabetes can't join. You also can't join if your liver enzymes, called ALT or AST, are too high (over 250). The study will compare two doses of pegozafermin.

• Study Duration: Participants need to be available for the entire study period, which includes regular visits.
• Eligibility: You need a biopsy confirming MASH with fibrosis stage 2 or 3.
• Risks & Benefits: There might be risks, but it could help improve liver health.